To prevent FOLFIRINOX-induced neutropenia, many clinicians consider the prophylactic administration of a granulocyte colony-stimulating factor (G-CSF), such as lipegfilgrastim, as standard therapy [9,10,11]. The gene discussed is CSF3; the disease is neutropenia.